Who Is a Good Candidate for GLP-1 Weight Loss Treatment?

You've heard the stories. A colleague lost 20 kilos. A friend says they finally feel in control of their appetite for the first time in years. The news won't stop talking about GLP-1 medications.

And now you're wondering: "Could this work for me?"

It's a perfectly reasonable question — and an important one. Because while GLP-1 treatments have genuinely transformed weight management for many people, they aren't designed for everyone. Not every person carrying extra weight is automatically a candidate. And understanding why certain criteria exist isn't about gatekeeping — it's about making sure these powerful medicines are used safely and effectively.

Let's walk through who GLP-1 weight-loss treatments are really for.

GLP-1 medications for weight management — like semaglutide (Wegovy) or liraglutide (Saxenda) — were developed for people dealing with obesity or serious weight-related health conditions. They were not designed for someone who wants to lose a few kilos before a wedding or fit into last year's jeans.

This distinction matters. These are prescription medications that alter how your body regulates hunger, blood sugar, and digestion. They come with potential side effects, require gradual dose increases over weeks, and need ongoing medical supervision.

Using them when they're not medically indicated isn't just unnecessary — it can be harmful. It also contributes to supply shortages that affect patients who genuinely need these medicines to manage serious health conditions.

So the first honest thing to say is: GLP-1 treatments are medical tools for medical problems. If your goal is cosmetic weight loss of a few kilos, your doctor will likely recommend lifestyle changes — diet, exercise, and behavioural strategies — which remain the foundation of healthy weight management for everyone.

Most clinical guidelines — and the criteria used in the large clinical trials — use a combination of Body Mass Index (BMI) and weight-related health conditions to determine eligibility.

Here's the general framework:

• BMI of 30 or above (classified as obesity) — typically eligible for GLP-1 weight-management treatment.
• BMI of 27 or above with at least one weight-related health condition — also typically eligible. These conditions include Type 2 diabetes, high blood pressure (hypertension), high cholesterol (dyslipidaemia), obstructive sleep apnoea, and cardiovascular disease, among others.

Now, a quick note about BMI. It's a useful screening tool, but it's not perfect. BMI doesn't distinguish between muscle and fat, and it doesn't account for where fat is stored in your body. South Asian populations, for instance, tend to develop metabolic complications at lower BMIs than Western populations — which is why some guidelines in India and other Asian countries use adjusted thresholds.

Your doctor will consider BMI as one piece of the puzzle, alongside your waist circumference, body composition, blood work, and overall health picture.

This is where things get personal — and where a proper medical screening becomes non-negotiable.

GLP-1 medications are not safe for everyone. Certain medical conditions and histories can make these treatments risky or outright unsuitable. Here are some of the key considerations your doctor will evaluate:

Thyroid Concerns

In animal studies, semaglutide and other GLP-1 receptor agonists were associated with thyroid C-cell tumours. While this hasn't been confirmed in humans, the precautionary principle applies. If you have a personal or family history of medullary thyroid carcinoma (MTC) — a specific type of thyroid cancer — or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), GLP-1 medications are generally contraindicated, meaning they should not be used.

Pancreatitis

There have been reports of pancreatitis (inflammation of the pancreas) in some patients taking GLP-1 medicines. If you have a history of pancreatitis, your doctor will weigh this risk very carefully before prescribing.

Gallbladder Disease

Rapid weight loss — from any cause — can increase the risk of gallstones. Since GLP-1 treatments can lead to significant weight loss, patients with a history of gallbladder problems need monitoring.

Kidney Function

Severe gastrointestinal side effects like vomiting or diarrhoea can lead to dehydration, which can worsen kidney function. Patients with existing kidney disease require closer monitoring.

Pregnancy and Breastfeeding

GLP-1 medications are not recommended during pregnancy or breastfeeding. If you're planning to become pregnant, your doctor will advise you to stop the medication well in advance — current guidance suggests at least two months before a planned pregnancy for semaglutide.

Other Medications

Because GLP-1 treatments slow down stomach emptying, they can affect how your body absorbs other oral medications. Your doctor will review everything you're currently taking — including diabetes medicines, blood pressure medications, and oral contraceptives — to check for interactions.

This list isn't exhaustive, which is exactly why a thorough medical evaluation is the essential first step. No blog post, no matter how detailed, can replace a doctor reviewing your specific medical history.

Here's a truth that can be frustrating to hear: having extra weight doesn't automatically mean you need — or should use — a GLP-1 medication.

Why? Because weight is complex, and the right approach depends on your individual situation.

Consider these scenarios:

• A person with a BMI of 25 who wants to lose 5 kg. They're in the "overweight" range but have no metabolic complications. For them, structured lifestyle changes — better nutrition, regular physical activity, improved sleep — are likely the most appropriate and effective approach. A GLP-1 medication would be medically unnecessary and wouldn't typically be prescribed.
• A person with a BMI of 32 who has tried diet and exercise programmes over several years without sustained success, and who also has pre-diabetes. This person has a clinical need. Lifestyle changes alone haven't been sufficient, and they have a weight-related health condition progressing toward diabetes. A GLP-1 treatment could be a meaningful addition to their management plan.
• A person with a BMI of 29 who has well-controlled health markers and is steadily losing weight with current lifestyle changes. Even though their BMI is close to the threshold, they may not need medication right now. Their current approach is working.

The point is that candidacy isn't just about a number on a scale or a BMI calculation. It's about the full clinical picture: your health risks, your history of weight-management efforts, your current health conditions, and the likely benefit-to-risk ratio of adding medication.

We've said it a few times already, but it bears repeating with emphasis: do not start a GLP-1 medication without proper medical screening.

Here's what a good screening process looks like:

• A detailed health history review — including past illnesses, surgeries, family history of thyroid cancer or pancreatitis, current medications, and any history of eating disorders.
• A physical assessment — weight, height, BMI, waist circumference, blood pressure.
• Blood work — including fasting blood sugar, HbA1c (a measure of long-term blood sugar control), kidney function, liver function, thyroid function, and a lipid profile.
• A discussion about goals and expectations — what you're hoping to achieve, what realistic outcomes look like, and how medication fits alongside lifestyle changes.
• A plan for ongoing monitoring — regular check-ins to track progress, manage side effects, adjust dosing, and repeat blood work as needed.

This process exists to protect you. GLP-1 medicines are powerful and effective, but they work best — and most safely — when they're part of a supervised, personalised treatment plan.

Buying medication online without a prescription, borrowing someone else's pen, or adjusting your own dose based on internet advice — these are genuinely dangerous shortcuts that put your health at risk.

Something that often gets lost in the global conversation about GLP-1 treatments: what's approved where matters.

The US FDA, the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organisation (CDSCO) are independent bodies. A medicine approved for weight management in the United States is not automatically approved for the same use in India.

Specific brand names, approved indications (diabetes versus weight management), and available doses can differ significantly between countries. In India, your doctor will know which GLP-1 products are currently available and approved, and for which conditions.

This is particularly important because international media coverage overwhelmingly focuses on US and European approvals. Reading that a drug is "FDA approved for weight loss" doesn't tell you anything about its regulatory status in India. Always check with your doctor about what's legally available and medically appropriate in your specific context.

If you've read this far and you're thinking, "Okay, I think I might be a candidate — but how do I actually find out?" — that's exactly what Zelta is built for.

Zelta is a telehealth platform designed to make this process accessible, thorough, and judgement-free. Here's how it works:

• Start with an online health assessment. You'll answer questions about your weight history, health conditions, medications, lifestyle, and goals. This isn't a quiz — it's a structured medical intake designed to give a doctor a clear picture of your situation.
• Get matched with a licensed clinician. A qualified doctor reviews your assessment, asks follow-up questions if needed, and evaluates whether a GLP-1 treatment might be appropriate for you.
• Receive a personalised recommendation. Based on your health profile, your doctor will explain your options clearly — whether that's a GLP-1 medication, a different approach, or a combination. If you're not a candidate, they'll tell you honestly and suggest alternatives.
• Ongoing support if you proceed. If treatment is prescribed, Zelta provides continued medical supervision — dose adjustments, side-effect management, progress tracking, and regular check-ins with your care team.

The process starts with a free online health assessment. If you choose to book a specialist consultation, a one-time fee applies. If you proceed with a treatment plan, the amount paid is adjusted against the plan price.

Because here's what we believe: everyone deserves a clear, medically informed answer to the question "Is this right for me?" — not a sales pitch, and not a guessing game.

GLP-1 weight-loss treatments are genuinely effective for the right patients. But "right" means medically appropriate — not just interested or hopeful.

Good candidates generally have:

• A BMI of 30 or above, or a BMI of 27 or above with weight-related health conditions.
• A history of attempting lifestyle-based weight management without sustained success.
• No medical contraindications that make GLP-1 treatment unsafe.
• Realistic expectations and a willingness to combine medication with ongoing healthy habits.
• Access to medical supervision throughout their treatment.

If that sounds like it could be you, the next step is simple: talk to a doctor.

Book a specialist consultation with Zelta today and find out where you stand — clearly, honestly, and with proper medical guidance behind every recommendation. A one-time consultation fee applies. If you proceed with a treatment plan, the amount paid is adjusted against the plan price.

This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan. Eligibility criteria described here are general guidelines — your doctor will assess your individual circumstances. BMI thresholds and approved indications may vary by country and by specific regulatory body. Drug availability in India is subject to CDSCO approvals and may differ from international markets. Zelta does not encourage self-diagnosis or self-medication.